Molecular Imaging in Radiation Oncology - Estro-events.org

Molecular 

Imaging in 

Radiation 

Oncology 

M 

I 

R 

O 

Programme & exhibition guide 

www.estro.org 

18-20 March 2010 

BRussels < BelgIuM

MIRO 

International conference on 

MOleculaR IMagIng In 

RadIatIOn OncOlOgy 

18-20 March, 2010 • BRussels, BelgIuM 

POSTERS

Contents 

> IntROductIOn p 4 

> cOMMIttees p 6 

> GeneRal InfORMatIOn p 7 

> acknOwledGeMents p 10 

> exhIbItIOn p 11 

> satellIte syMpOsIa p 15 

> scIentIfIc pROGRaMMe p 19 

> pOsteRs p 29 

> authOR’s Index p 43 

MIRO • Programme & exhibition guide Page 3

Introduction 

Over the last decade Molecular Imaging with positron emission 

tomography has emerged as a complementary modality to anatomic 

imaging methods for better staging and treatment response evaluation 

in clinical oncology. fluorodeoxyglucose has been recognized as a 

universal radiopharmaceutical for many solid tumours. Methionine 

has proven its value for intracranial tumours and other tracers, such 

as fluoro-choline, are finding their ways to routine clinical practice. 

tracers of hypoxia and proliferation are emerging to characterize the 

tumour biology and potentially influence the treatment choice. And 

many new tracers are on their way… 

Molecular Imaging is also being evaluated for its ability to help 

define target volumes for radiotherapy by introducing the biological 

component of tumour and normal tissues. such an approach could 

potentially lead to delivering a more adequate dose to some part 

of the target volume, thus paving the way for the concept of “dose 

painting”. 

and this is just the beginning with many more challenges ahead of us! 

In this thrilling environment, the european society for therapeutic 

Radiology and Oncology (estRO) and the european association for 

nuclear Medicine (eanM) have the pleasure to invite you to participate 

to the first MOLECULAR IMAGING IN RADIATION ONCOLOGY (MIRO) 

meeting that will be held in brussels (belgium) on the 18 th -20 th March 

2010. 

with major emphasis on MULTIDISCIPLINARY AND INNOVATION, this 

conference will more specifically cover the following topics: 

• Methodological approaches in Molecular Imaging 

• Molecular Imaging to decipher tumour biology 

• New tracers: beyond FDG 

• Molecular Imaging to personalize treatment in oncology 

• state of the art and future prospects in the clinical use of Molecular 

Imaging in radiation oncology 

• Molecular Imaging radiation dose painting 

the format of the conference will combine “state of the art lectures”, 

lectures on innovative approaches, and proffered papers. ample time 

will be given for discussions to allow in-depth interactions among the 

various disciplines and the participants. 

It is hoped you will enjoy the mix of a rich and challenging scientific 

programme, and the never-ending attraction of the city of brussels. 

Conference Chairpersons 

prof. Vincent Grégoire prof. wolfram knapp 

Past President of ESTRO President of EANM 

Page 4 Programme & exhibition guide • MIRO MIRO • Programme & exhibition guide Page 5

Committees General Information 

scIentIfIc pROGRaMMe cOMMIttee 

Chairpersons: Vincent Grégoire (be) and wolfram knapp (de) 

Members: Markus alber (de), Martin behe (de), Ronald boellard (nl), Jean bourhis (fR), 

arturo chiti (It), karin haustermans (be), cristina Messa (It), wim Oyen (nl), 

daniel Zips (de) 

clInIcal cOMMIttee 

Chairpersons: bernard dubray (fR) and francesca pons (es) 

Members: andrew chan (hk), wilfried budach (de), christina Gamez (es), cécile le 

pechoux (fR), ursula nestlé (de), chris nutting (uk), Jaap teule (nl), 

damien weber (ch), wai lup wong (uk) 

physIcs cOMMIttee 

Chairpersons: Michael lassmann (de) and ludvig Muren (dk) 

Members: Manuel bardies (fR), alberto del Guerra (It), Robert Jeraj (usa), 

dag Rune Olsen (nO), stig palm (at), daniela thorwarth (de) 

pRe-clInIcal cOMMIttee 

Chairpersons: Jan bussink (nl) and Ivan penuelas (es) 

Members: bettina beuthien-baumann (de), Morten busk (dk), clemens decristoforo (at), 

bengt langstrom (se), steve Mather (uk), heikki Minn (fI) 

cOnfeRence secRetaRIat 

agostino barrasso (conference Manager) 

Eralda Azizaj & Lea Minnen (Scientific Programme Managers) 

Valérie cremades (exhibition coordinator) 

Jill barnard (Registration coordinator) 

Venue 

sQuaRe – bRussels MeetInG centRe 

Museumstraat 8 Rue du Musée 

1000 brussels 

www.square-brussels.com 

accOMMOdatIOn 

MCI is the official accommodation agent for the conference and will operate an accommodation 

desk in the registration area on: 

thursday 12.00 - 17.00 

friday 09.00 - 17.00 

saturday 09.00 - 11.00 

accRedItatIOn 

the « acOe (accreditation council of Oncology in europe) » (or) « MIRO (Molecular Imaging 

in Radiation Oncology) » is accredited by the european accreditation council for 

continuing Medical education (eaccMe) to provide the following cMe activity for medical 

specialists. the eaccMe is an institution of the european union of Medical specialists 

(ueMs), www.uems.net. 

the « MIRO (Molecular Imaging in Radiation Oncology) » is designated for a maximum of 

12 hours of european external cMe credits. each medical specialist should claim only those 

hours of credit that he/she actually spent in the educational activity. 

eaccMe credits are recognized by the american Medical association towards the physician’s 

Recognition award (pRa). to convert eaccMe credit to aMa pRa category 1 credit, contact 

the aMa. 

badGes 

upon registration you will receive a personal name badge. you and your partner (if 

registered as accompanying person) are kindly requested to wear this badge when 

attending scientific sessions and/or social events. 


General Information 

ceRtIfIcates 

Certificates of attendance will be issued as of Friday March 19 in the afternoon through 

the designated stations in the registration area. 

participants are kindly requested to complete the conference general evaluation form 

in return for a certificate. 

Certificates of attendance can also be downloaded online through our website after 

the event. 

cuRRency 

the currency in belgium is the euro. 

exhIbItIOn 

an exhibition will be held in the exhibition area. the exhibition will be open on thursday 

March 18, 2010 at 18:00, on Friday 19 between 09:30 and 17:00 and Saturday 20 between 

9:30 and 11:00. Entrance is free of charge for all participants and registered accompanying 

persons. 

InsuRance 

the organiser does not accept liability for individual medical, travel or personal insurance. 

participants are strongly advised to take out their own personal insurance 

policies. 

In case an unforeseen event would force estRO to cancel the meeting, the society will 

reimburse the participants the registration fee minus 15% for handling charges. estRO 

will not be responsible for the refund of travel and accommodation costs. 

luncheOns and RefReshMents 

the registration fee for the meeting includes lunch on friday 19 March. Refreshments 

will be served during coffee breaks to all participants and exhibitors wearing their 

conference badges. 

satellIte syMpOsIa 

commercial satellite symposia will be held during the conference (see programme 

on p.15). 

sMOkInG 

there will be a strict non-smoking policy within all areas of the conference facilities 

used for the meeting. 

sOcIal actIVItIes 

all participants, registered accompanying persons and all company delegates are invited 

to the official opening ceremony which will be held in the main auditorium on Thursday 

18 March at 15:00. The welcome reception will take place in the exhibition area at 

18.00. 


acknowledgements 

estRO, the european society for therapeutic Radiology and Oncology and eanM, the 

European Association of Nuclear Medicine wish to thank for their support to this meeting: 

Page 10 Programme & exhibition guide • MIRO 

GE Healthcare 

Ion Beam Applications (IBA) 

all companies having supported the participation of some delegates in the meeting 

and/or participating in the technical exhibition. 

a special thank you to Vincent Grégoire and wolfram knapp for having accepted the 

responsibility to develop the scientific programme for this conference. 

exhibition

ExhIbITION 

Technical Exhibition 

aQuIlab 4 

Ge healthcaRe 7 

heRMes MedIcal sOlutIOns ltd 2 

IasOn Gmbh 6.5 

Iba 6 

MIMvista corp 5 

phIlIps healthcaRe nedeRland bV 3 

sIeMens aG, healthcaRe sectOR 1 

exhIbIt hall flOOR plan 

catering area 


1 

6 

2 3 

ESTRO 

ESTRO 

6.5 

7 

4 

5 

lounge area 

poster area 

Main entrance 

Companies 

aQuIlab 4 

parc eurasanté – lille Métropole 

407 rue salvador allende 

59120 loos les lille, france 

www.aquilab.com 

Tel.: +33 (0) 3 69 61 51 51 

Fax: +33 (0) 3 69 61 51 50 

Contact: David Gibon, President & CEO 

E-mail: david.gibon@aquilab.com 

henri pierre Justin, Sales Director 

E-mail: henri.pierre-justin@aquilab.com 

General e-mail: info@aquilab.com 

AQUILAB develops software solutions to 

enhance quality and precision in Nuclear 

Medicine and Radiotherapy (contouring, 

fusion, collaborative work, dose and contours 

evaluation and review, quality assurance). 

Ge healthcare 7 

283 Rue de la Miniere 

78533 buc, france 

www.gehealthcare.com 

Tel.: +33 (0) 1 30 70 44 08 

Fax: +33 (0) 1 30 70 91 60 

Contact: Cécile Finck, PET/CT Product 

Manager 

E-mail: cecile.finck@ge.com 

hermes Medical solutions ltd 2 

Grove house, 2 Orange street 

london wc2h 7df, uk 

www.hermesmedical.com 

Tel.: + 44 (0) 20 3178 5890 

Fax: + 44 (0) 20 3178 6101 

Contact: Wendy O’Hanlon, Customer 

Services Manager UK 

E-mail: wendy@hermesmedical.com 

IasOn Gmbh 6.5 

feldkirchnerstrasse 4 

8054 Graz seiersberg 

www.iason.eu 

Tel.: +43 (316) 284300 DW 13 

Fax: +43 (316) 284300 DW 4 

Contact: Nadine Gspandl 

E-mail: office@iason.eu 

Iba 6 

chemin du cyclotron 3 

1348 louvain-la-neuve, belgium 

www.iba-worldwide.com 

Tel.: +32 (0) 10 475 811 

Fax: +32 (0) 10 475 810 

Contact: Thomas Ralet 

E-mail: info-worldwide@iba-group.com 

IBA develops and markets leading edge technologies, 

pharmaceuticals and tailor-made 

solutions for healthcare with a focus on cancer 

diagnosis and therapy. Leveraging on its 

scientific expertise, IBA is particularly active 

in the field of Molecular Imaging, Dosimetry 

and Proton Therapy. 

MIRO • Programme & exhibition guide Page 13 

ExhIbITION

ExhIbITION 

Companies 

MIMvista corp. 5 

25200 chagrin blvd. suite 200, cleveland 

Oh 44122, usa 

www.mimvista.com 

Tel.: + 1 866-421-2536 

Fax: + 1216-455-0601 

Contact: Megan Hottle 

E-mail: mhottle@mimvista.com 

philips healthcare nederland b.V. 3 

Vb3-340a, postbus 90050 

5600 pb eindhoven, the netherlands 

www.philips.com/healthcare 

Tel.: +31 (0) 40-27 85 600 

Fax: +31 (0) 40-27 80 160 

Philips is one of the world’s leading technology 

companies, with a long history of practical innovation 

and visionary design. In healthcare, 

we are committed to understanding the human 

and technological needs of patients and caregivers. 

We believe this understanding will help 

us deliver solutions that not only enable more 

confident diagnoses and more efficient delivery 

of care, but also improve the overall experience 

of care. We offer equipment, software, and services 

for imaging, patient monitoring, resuscita- 

tion and much more. Visit us at our booth to learn 

more. People focused. Healthcare simplified. 


siemens aG, healthcare sector 1 

henkestr. 127, 

91052 erlangen, Germany 

www.siemens.com/healthcare 

Tel.: +49 (0) 9131/84-0 

Fax: +49 (0) 9131/84-2924 

E-mail: medg.gms@siemens.com 

Satellite SymPoSia

SATELLITE SYMPOSIA 

Satellite Symposium 

GE Healthcare 

MaRch 18, 2010 

12:30 TO 14:30 

cOppeR hall 


tOwaRds hIGheR pRecIsIOn - 

the use Of pet/ct In RadIOtheRapy 

1. the use of 4d pet/ct for Rt planning 

doctor Maria picchio 

San Raffaele Scientific Hospital, Milan, Italy 

2. the use of pet/ct for planning in head & neck cancer 

doctor Marta paiusco 

Arcispedale S.M. Nuova, Reggio Emilia, Italy 

3. dose escalation in prostate cancer IMRt using pet/ct 

professor heikki Minn 

Turku University Central Hospital, Turku, Finland 

4. new tools for Multi-Modality Image Management 

doctor kirstin schmiedehausen 

Varian Medical Systems Inc, Palo Alto CA, USA 

Satellite Symposium 

IBa 

MaRch 19, 2010 

fROM 12.30 tO 14.20 

cOppeR hall 

PET IMAGING OF APOPTOSIS: 

pOtentIalItIes fOR MOleculaR IMaGInG 

and RadIatIOn OncOlOGy 

chaired by prof. peter J. ell 

Chair, Nuclear Medicine, University of London 

Director, Institute of Nuclear Medicine, University College London 

Fellow, Academy of Medical Sciences, London 

1. from the Gla domain to a novel small-molecule detector 

of apoptosis 

anat shirvan phd 

Israel 

2. first experiences of 18f-Ml-10 in the monitoring of 

radiation oncology 

aaron M. allen Md 

USA 

3. 18F-ML-10: Potential applications of PET imaging of 

apoptosisin radiation oncology 

daniel Zips Md 

Germany 


SATELLITE SYMPOSIA

Scientific Programme

Copper Hall 

OPENING CEREMONY 

Chair: V. Grégoire, Belgium 

W. Knapp, Germany 

Thursday, March 18, 2010 

15:00 - 16:00 • Opening ceremony 

1 15:15 

HIGH-TECH MEDICINE IN THE FIGHT AGAINST CANCER - HOW MUCH 

MOLECULAR IMAGING DO WE NEED 

M. Schwaiger (Germany) 


SCIENTIFIC PROGRAMME

SCIENTIFIC PROGRAMME 

Thursday, March 18, 2010 

16:00 - 18:00 • Symposium 

Copper Hall 

NEW PERSPECTIVES AND CHALLENGING ISSUES IN MOLECULAR IMAGING FOR 

RADIATION ONCOLOGY 



2 16:00 

EUROPEAN REGULATIONS ON RADIOPHARMACEUTICALS - A PROFES- 

SIONAL’S PERSPECTIVE 

C. Decristoforo (Austria) 

33.1 16:30 

CLINICAL TRIAL PROSPECTIVE 

S. Stroobants (Belgium) 

3.2 

3.3 

17:00 

REGULATION FROM THE EUROPEAN POINT OF VIEW 

17:30 

ROUND TABLE DISCUSSION 


Copper Hall 

MULTI-TRACERS FOR MOLECULAR PROFILING 

Chair: D. Zips, Germany 

S. Stroobants, Belgium 

Friday, March 19, 2010 

08:45 - 10:30 • Symposium 

4 08:45 

TUMOR MICROENVIROMENT AND CELLULAR ADAPTATION: OPPORTUNI- 

TIES FOR IMAGING 

B. Wouters (Canada) 

5 09:15 

HOW TO IMAGE (TRACERS). STATE OF THE ART AND FUTURE DEVELOP- 

MENT 

C. Halldin (Sweden) 

6 09:45 

HOW TO IMAGE QUANTITATIVELY? STATE OF THE ART AND FUTURE EQUIP- 

MENT DEVELOPMENT 

R. Boellaard (Netherlands) 

10:15 

DISCUSSION TIME 





11:00 - 12:30 • Symposium 

Copper Hall 

TRANSLATING MOLECULAR IMAGING INTO CLINICAL PRACTICE 

Chair: K. Haustermans, Belgium 

P. Vera VERA, France 

7 11:00 

THE EGFR STORY FROM A MOLECULAR IMAGING POINT OF VIEW 

G. Van Dongen (Netherlands) 

8 11:25 

TUMOR MICROENVIRONMENT INCLUDING HYPOXIA 

B. Beuthien-Baumann (Germany) 

9 11:50 

SIMULATION OF HYPOXIA PET TRACER DYNAMICS BASED ON TUMOUR 

TISSUE MICROSECTIONS 

D. Mönnich (Germany), D. Thorwarth, E. Troost, J. Kaanders, W. Oyen, M. Alber 

10 12:00 

PET-IMAGING OF HYPOXIA USING 89ZR-LABELED CG250-F(AB’)2 

B. Hoeben (Netherlands), J. Kaanders, P. Laverman, E. Oosterwijk, W. Oyen, O. Boerman, 

J. Bussink 

11 12:10 

PRECLINICAL EVALUATION OF [18F]HX4, A NOVEL AND PROMISING HY- 

POXIA MARKER FOR PET IMAGING 

L. Dubois (Netherlands), N. Lieuwes, M. Janssen, J. Secrest, A. Windhorst, G. Van 

Dongen, H. Kolb, M. Öllers, J. Zhang, P. Lambin 

12 12:20 

TARGETING THE LACTATE TRANSPORTER MCT1 INDUCES A METABOLIC 

REARRANGEMENT THAT RADIOSENSITIZES TUMORS 

P. Sonveaux (Belgium), F. Végran, M. Dewhirst, O. Feron 


Copper Hall 

TREATMENT SELECTION 

Chair: D. De Ruysscher, Netherlands 

W. Weber, Germany 


14:30 - 16:00 • Symposium 

13 14:30 

IMPACT ON DISEASE STAGING BY NEW IMAGING MODALITIES 

T. F. Hany (Switzerland) 

14 14:55 

TUMOUR BIOLOGY-GUIDED PROGNOSTICATION OF TREATMENT RE- 

SPONSE 

H. Minn (Finland) 

15 15:20 

SCREENING FOR DISTANT METASTASES IN HEAD AND NECK CANCER PA- 

TIENTS BY FDG-PET(-CT) TO AVOID FUTILE TREATMENTS 

R. de Bree (Netherlands), A. Senft, O. Hoekstra, D. J. Kuik, R. Golding, E. Comans, C. 

R. Leemans 

16 15:30 

PET TO AVOID FUTILE LARYNGOSCOPIES IN PATIENTS WITH SUSPICION 

OF RECURRENT LARYNGEAL CARCINOMA AFTER RADIOTHERAPY 

R. de Bree, L. Van der Putten (Netherlands), O. Hoekstra, D. J. Kuik, E. Comans, C. R. 

Leemans 

17 15:40 

ROLE OF 18F-FDG PET/TC IN THE PREDICTION OF RESPONSE TO NEO- 

ADJUVANT CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: OUR EXPE- 

RIENCE 

F. Matteucci (Italy), A. Marzullo, A. Moretti, R. Galassi, F. Lio, A. Moro, P. Morgagni, G. 

M. Vverdecchia 

18 15:50 

PRETREATMENT F-MISO HYPOXIC VOLUME IS PROGNOSTIC FOR LOCAL 

CONTROL AFTER SINGLE DOSE IRRADIATION IN FADU HSCC 

B. Beuthien-Baumann (Germany), C. Schütze, R. Bergmann, B. Mosch, A. Yaromina, K. 

Brüchner, R. Greinke, F. Hessel, H. Thames, D. Zips, P. Mäding, M. Baumann 





16:30 - 18:00 • Symposium 

Copper Hall 

TARGET SELECTION / DELINEATION 

Chair: J. Bussink, Netherlands 

P. Flamen, Belgium 

19 16:30 

SEGMENTATION, (AUTO) DELINEATION, 4D PET/CT 

J. Nuyts (Belgium) 

20 16:55 

CLINICAL REQUIREMENTS FOR TARGET VOLUME SELEC- 

TION/DELINEATION 

U. Nestle (Germany) 

21 17:20 

USE OF GA-68-DOTATOC PET/CT FOR PLANNING THE STEREOTACTIC RT 

IN SCULL BASE MENINGIOMAS 

F. Nyuyki (Germany), R. Graf, D. Fahdt, R. Michel, L. Geworski, W. Brenner, M. Plotkin 

22 17:30 

FDG-PET GUIDED IMRT FOR PATIENTS WITH CERVICAL CANCER 

P. S. Grigsby Richardson (USA) (USA) 

23 17:40 

IMPACT OF 18-FDG PET STAGING ON TREATMENT PLANNING IN RADIO- 

THERAPY INCORPORATING ELECTIVE NODAL IRRADIATION FOR NON- 

SMALL CELL LUNG CANCER: PROSPECTIVE STUDY . 

M. Kolodziejczyk (Poland), L. Kepka, M. Dziuk, A. Zawadzka, N. Szalus, A. Gizewska, 

K. Bujko 

24 17:50 

FIRST RESULTS FROM LIST MODE BASED TARGET DELINEATION IN HIGH 

PRECISION RADIOTHERAPY 

I. Ernst (Germany), F. Buether, M. Dawood, P. Kraxner, C. Moustakis, M. Weckesser, O. 

Schober, K. Schäfers, N. Willich, T. Boelling 


Copper Hall 

DOSE PAINTING 

Chair: E. Lartigau, France 

J. Nuyts, Belgium 

Saturday, March 20, 2010 

08:30 - 10:00 • Symposium 

25 08:30 

DOSE-REDISTRIBUTION IN NON-SMALL CELL LUNG CANCER: IMAGING 

NEEDS AND FIRST CLINICAL EXPERIENCE 

D. De Ruysscher (Netherlands) 

26 08:55 

PHYSICAL CONCEPTS/POTENTIAL LIMITATIONS/POTENTIAL ADVANTAGES 

M. Alber (Germany) 

27 09:20 

INTENSITY-MODULATED RADIOTHERAPY FOR PROSTATE CANCER IMPLE- 

MENTING MOLECULAR IMAGING WITH 18F-CHOLINE PET-CT TO DEFINE A 

SIMULTANEOUS INTEGRATED BOOST 

M. Pinkawa (Germany), M. Piroth, R. Holy, J. Klotz, S. Nussen, T. Krohn, F. Mottaghy, 

M. Eble 

28 09:30 

BIOLOGICAL TARGET VOLUME (BTV) BOOST PHASE II STUDY ON DOSE- 

ESCALATION OF THE HIGH UPTAKE FDG-PET REGIONS INSIDE THE PRI- 

MARY TUMOUR FOR NSCLC: THE TREATMENT PLANNING STRATEGY 

W. van Elmpt (Netherlands), S. Petit, A. van der Salm, J. van der Stoep, A. Lakeman, J. 

J. Sonke, E. Damen, M. Öllers, J. Belderbos, D. De Ruysscher 

29 09:40 

PET-GUIDED DOSE PAINTING FOR MOVING TUMORS OF THE LUNG: A PRE- 

LIMINARY ANALYSIS CONTRASTING 3D AND 4D SCANS 

M. Aristophanous (USA), A. Chen, J. Yap, J. Killoran, S. J. Park, R. Berbeco 

30 09:50 

OPTICAL IMAGING OF TUMOR RESPONSE TO RADIATION: PROBING VAS- 

CULAR, CELLULAR AND MOLECULAR CHANGES IN VIVO 

R. DaCosta (Canada), M. Leung, E. Chen, P. Lindsay, D. Jaffray, A. Vitkin, R. Hill 




Saturday, March 20, 2010 

10:30 - 12:00 • Symposium 

Copper Hall 

WHEN, HOW AND WHY MOLECULAR IMAGING FOR RESPONSE EVALUATION AND 

FOLLOW UP 



31 10:30 

RADIATION ONCOLOGY PERSPECTIVE 

K. Haustermans (Belgium) 

32 10:55 

NUCLEAR MEDICINE PERSPECTIVE 

W. Weber (Germany) 

33 11:20 

ROLE OF 11C-CHOLINE PET/CT IN TOMOTHERAPY TREATMENT PLANNING 

OF LYMPH NODAL RELAPSE IN PROSTATE CANCER PATIENTS 

M. Picchio (Italy), F. Alongi, E. Manca, C. Cozzarini, G. Berardi, C. Landoni, L. Gianolli, 

N. Di Muzio, C. Messa 

34 11:30 

THE ROLE OF 18FDG-PET -CT IN RESPONSE PREDICTION BEFORE, DUR- 

ING AND AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR RECTAL 

CANCER. 

M. Lambrecht (Belgium), C. Deroose, S. Roels, L. Mortelmans, F. Penninckx, E. Van 

Cutsem, K. Haustermans 

35 11:40 

FLT-PET-CT FOR EARLY TREATMENT RESPONSE MONITORING IN HEAD 

AND NECK TUMOURS 

E. Troost (Netherlands), J. Bussink, A. Hoffmann, O. Boerman, W. Oyen, J. Kaanders 

36 11:50 

HYPOXIA IMAGING DURING RADIOCHEMOTHERAPY IN PATIENTS WITH LO- 

CALLY ADVANCED HEAD-AND-NECK CANCER 

D. Zips (Germany), N. Abolmaali, K. Zöphel, A. Abramyuk, C. Reiffenstuhl, S. Appold, J. 

Kotzerke, J. Steinbach, M. Baumann 


PoSterS

BIOLOGICAL TREATMENT PLANNING 

Abstract 

Nb. 

37 

38 

39 

40 

41 

42 

43 

44 

PROMISING NEW ADVANCES TREATED AND DISCOVERY MOLECULAR 

BIOMARKER IN ADVANCED HEAD AND NECK CARCINOMA 

F. Badulescu, A. Badulescu, A. E. Crisan (Romania), M. Schenker, C. Popescu, S. Dinescu 

AN ASSESSMENT OF MOTION-BLURRING IN PET-GUIDED TREATMENT 

PLANNING USING A RADIOBIOLOGICAL ENDPOINT 

R. Perrin (United Kingdom), S. Webb, M. Partridge 

APOPTOSIS IMAGING BY PET 18F-ML-10: A POTENTIAL TOOL FOR RADIA- 

TION DOSE PAINTING 

A. Shirvan (Israel), T. Davidson, A. Allen, A. Reshef, A. Steinmetz, I. Ziv 

BIOLOGICAL IN-SITU DOSE PAINTING FOR IGRT (BIS-IGRT) BY USE OF 

DRUG-LOADED IMPLANTABLE FIDUCIALS AND SPACERS 

M. Makrigiorgos (USA), S. Sridhar, A. D’Amico, P. Nguyen, R. Cormack 

BIOLOGICALLY GUIDED RADIATION THERAPY: QUALITY ASSURANCE AND 

RESOURCE IMPLICATIONS IN LONGITUDINAL PET/CT STUDIES 

S. Everitt (Australia), J. Callahan, T. Kron, R. Hicks, D. Ball, M. Schneider-Kolsky, M. 

Mac Manus 

COMPARISON BETWEEN CT-TARGET VOLUME DELINEATION AND DIFFER- 

ENT METHODS OF FDG-PET TARGET VOLUME DELINEATION FOR RADIO- 

THERAPY PLANNING OF NSCLC 

M. Rodari (Italy), P. Navarria, P. Lattuada, M. Scorsetti, A. Chiti 

DYNAMICS OF HYPOXIA IN HEAD AND NECK CANCER DURING CHEMORA- 

DIOTHERAPY EVALUATED WITH [18]F-FLUOROMISONIDAZOLE PET 

N. Wiedenmann (Germany), M. Mix, S. Bucher, S. Adebahr, C. Offermann, U. Nestle, 

W. Weber, A. L. Grosu, M. Hentschel 

PET ASSESSMENT OF TUMOR PROLIFERATION, METABOLISM AND HY- 

POXIA BEFORE AND DURING RADIOTHERAPY IN PATIENTS WITH NON 

SMALL CELL LUNG CANCER (NSCLC) 

B. Dubray (France), P. VERA, A. Edet-Sanson, P. Bohn, A. Salles, S. Hapdey, I. Gardin, 

J. Menard, L. Thiberville 


POSTERS

POSTERS 

Abstract 

Nb. 

45 

46 

47 

48 

49 

DOSE PAINTING 

PET-CT BASED TARGET DELINEATION FOR INTENSITY MODULATED RA- 

DIOTHERAPY PLANNING IN A CASE OF CARCINOMA ESOPHAGUS 

G. Saini (India), V. Goel, A. Anand, K. Gupta, A. MIshra 

QUANTITATIVE SPECT FOR PRE-THERAPEUTIC ASSESSMENT OF SIR- 

SPHERES DISTRIBUTION 

D. Bailey (Australia), K. Willowson, C. Baldock 

TECHNOLOGY DEVELOPMENT IN THE PLANNING OF PET-FDG AIDED RA- 

DIOTHERAPY FOR CHEST CANCER. A JOINT DEPARTMENTAL HISTORY. 

L. Leonardi (Italy), G. Testanera, A. Modugno, P. Lattuada, R. Barisonzi, M. Scorsetti, A. 

Chiti 

TREATMENT REGIMEN DETERMINES WHETHER A HIF-1 INHIBITOR EN- 

HANCES OR INHIBITS THE EFFECT OF RADIATION THERAPY 

H. Harada (Japan), S. Itasaka, M. Hiraoka 

USING [18F]FLT-PET IMAGING IN IMRT PLANNING TO AVOID PELVIC BONE 

MARROW FOR CERVICAL CANCER PATIENTS 

S. McGuire (USA), G. Jacobson, Y. Menda, L. Ponto, B. Gross, J. Malik, J. Bayouth 

Abstract 

Nb. 

50 ADAPTATION OF TREATMENT IN RADIATION DOSE PAINTING 

A. Soevik (Norway), E. Malinen, D. R. Olsen 

51 

EX VIVO STUDIES AND FIRST CASE REPORTS: PET/CT BASED GOLDEN 

MARKER IMPLANTATION FOR IMAGE GUIDED HIGH PRECISION RADIO- 

THERAPY (IGRT) FOR HEAD AND NECK CANCER 

N. Blumstein (Switzerland), A. Arnold, T. Krause, C. Candreia, P. Zbären, D. M. Aebersold, 

M. Schmuecking 

52 IMAGING FOR DOSE PAINTING – WHAT DO WE NEED TO KNOW? 

C. South (United Kingdom), P. Evans, M. Partridge 

53 

IMPACT OF THE ACCURACY OF TUMOR FUNCTIONAL VOLUME DELIN- 

EATION ON RADIOTHERAPY TREATMENT PLANNING 

A. Le Maitre (France), M. Hatt, C. Cheze Le Rest, N. Albarghach, O. Pradier, D. Visvikis 


Abstract 

Nb. 

54 

IS THERE A ROLE FOR DOSE PAINTING WITHIN THE PROSTATE IN THE PRI- 

MAL THERAPY OF PATIENTS WITH LOCALIZED PROSTATE CANCER USING 

CHOLINE PET/CT, DYNAMIC MRI AND CAD OR CHOLINE MRS? 

M. Schmuecking (Germany), S. Perner, C. Boltze, H. Geyer, H. Salz, F. Finsterbusch, S. 

Reske, T. Wendt, C. Marx, N. Blumstein 

55 ON THE IMPACT OF FUNCTIONAL IMAGE ACCURACY ON DOSE PAINTING 

W. Tomé (USA), Y. Kim 

56 

THERAPY WITH RADIO LABELLED ANTIBODIES: A PATIENT-SPECIFIC CODE 

FOR ISODOSE QUANTIFICATION 

M. D’Arienzo (Italy), F. Cicone, L. Chiacchiararelli, F. Scopinaro, V. Brainovich 

INSTRUMENTATION/IMAGE GENERATION/DATA ANALYSIS 

Abstract 

Nb. 

57 

58 

4D-PET ACQUISITION: COMPARISON BETWEEN 2 SYNCHRONIZATION DE- 

VICES 

J. Nalis (France), O. Caselles, L. Dierickx, S. Brillouet, Z. Ouskili, H. Batatia, S. Zerdoud, 

F. Courbon 

A NEW DATA BASED METHOD FOR ACQUIRING RESPIRATORY SIGNAL 

FROM RAW PET DATA TO BE USED FOR RESPIRATORY GATING 

A. Kesner (Austria) 

59 EFFECT OF RESPIRATION MOTION ON SUV ASSESSEMENT 

V. Longari (Italy), L. Calabrese, F. Zito, R. Lambertini, R. Leo, M. Rognoni, G. Marotta, 

P. Gerundini 

60 

61 

IMPACT OF THE IMAGE SPATIAL SAMPLING ON TUMOUR DETECTION IN 

18F-FDG PET 

R. Maroy (France), L. Saint Christophe, C. Lartizien, P. Merlet, C. Comtat, R. Trebossen 

INTEGRATION OF 3D MAGNETIC RESONANCE SPECTROSCOPY MAPS 

INTO TREATMENT PLANNING OF GLIOBLASTOMA 

S. Ken (France), X. Franceries, J. A. Lotterie, V. Lubrano, I. Catalaa, H. Metwaly, L. 

Vieillevigne, I. Berry, P. Celsis, E. Moyal-Cohen-Jonathan, A. Laprie 


POSTERS

POSTERS 

Abstract 

Nb. 

NEW RADIOPHARMACEUTICALS 

Abstract 

Nb. 

62 

63 

BREMSSTRAHLUNG IMAGING OF Y-90-MICROSPHERES SHOWS POOR RE- 

SEMBLANCE WITH DISTRIBUTIONS OF TC-99M-MAA IN LIVER 

J. Högberg (Sweden), M. Rizell, P. Gjertsson, R. Hultborn, O. Henriksson, J. Himmelman, 

P. Bernhardt 

COMPARISON BETWEEN 18F-CHOLINE UPTAKE AND CHOLINE DETECTION 

IN MR SPECTROSCOPY IN ONE CASE OF BRAIN TUMOUR 

R. Sghedoni (Italy), A. Gallina, A. Versari, F. Fioroni, A. Nitrosi, D. Salvo, M. Iori, G. 

Borasi 

PRE-CLINICAL VALIDATION OF TRACERS 

Abstract 

Nb. 

64 

65 

66 

CT/MR CONTRAST AGENT FOR LONGITUDINAL LOCALIZATION AND DELIN- 

EATION OF TARGET STRUCTURES IN IMAGE-GUIDED RADIOTHERAPY 

J. Zheng (Canada), C. Allen, D. Jaffray 

EARLY METABOLOC FLARE FOLLOWING CYTOTOXIC TREATMENT OF 

SQUAMOUS CELL CARCINOMA IN VITRO 

M. Bjurberg (Sweden), P. Abedinpour, E. Kjellen, B. Baldetorp, P. Borgström, J. Wennerberg, 

E. Brun 

IMAGING HYPOXIA RESPONSE USING FLUORESCENT AND FLUORINE-18 

LABELED SULFONAMIDE INHIBITORS OF CA IX 

L. Dubois, N. Lieuwes, J. Secrest, C. Supuran, B. Wouters, H. Kolb, P. Lambin (Netherlands) 


Abstract 

Nb. 

RESPONSE EVALUATION/FOLLOW UP 

Abstract 

Nb. 

67 

68 

69 

70 

71 

72 

18F-FDG PET/CT AS A SELECTION TOOL FOR IMAGE GUIDED RADIOTHER- 

APY (IGRT) IN PATIENTS WITH RECURRENT OR RESIDUAL OVARIAN CAN- 

CER 

C. Blumstein (Switzerland), M. Schmuecking, S. Gebhard, S. Perner, C. Kurzeder, S. 

Reske, D. M. Aebersold, N. Blumstein 

DIAGNOSTIC PERFORMANCE OF RESPONSE ASSESSMENT FDG-PET/CT 

IN PATIENTS WITH HEAD & NECK SQUAMOUS CELL CARCINOMA TREATED 

WITH HIGH-PRECISION DEFINITIVE (CHEMO)RADIATION 

T. Gupta (India), S. Jain, J. P. Agarwal, V. Rangarajan, S. Ghosh-Laskar, K. Dinshaw, N. 

Purandare 

EARLY PREDICTION OF TREATMENT RESPONSE IN XENOGRAFTS USING 

QUANTITATIVE DIFFUSION WEIGHTED MRI 

T. Seierstad (Norway), K. Røe, S. Folkvord, K. Flatmark, A. Skretting, D. R. Olsen 

INTRA-TREATMENT FDG POSITRON EMISSION TOMOGRAPHY RESPONSE 

ASSESSMENT OF ADVANCED HEAD AND NECK CANCER TREATED WITH 

RADIATION +/- CHEMOTHERAPY 

D. Vena (Canada), I. Poon, M. Kusano, B. Smith, S. Campbell, J. Balogh, R. G. MacKenzie, 

D. Enepekides, K. Higgins, J. Davidson, S. Singh, C. Caldwell 

IRON OXIDE PARTICLES COVERED WITH HEXAPEPTIDES TARGETED AT 

PHOSPHATIDYLSERINE AS MR BIOMARKERS OF TUMOR CELL DEATH 

K. Radermacher (Belgium), S. Boutry, S. Laurent, I. Mahieu, L. Vander Elst, C. Bouzin, 

J. Magat, V. Grégoire, O. Feron, R. Muller, B. Jordan, B. Gallez 

MOLECULAR IMAGING OF RADIATION RESPONSE IN PRECLINICAL MOD- 

ELS USING A NOVEL SMALL ANIMAL RADIOTHERAPY SYSTEM 

G. Nelson (USA), M. Vilalta, J. Pérez, M. Bazalova, A. Giaccia, E. Graves 


POSTERS

POSTERS 

Abstract 

Nb. 

73 

74 

75 

76 

77 

MOLECULAR REMISSION AFTER NEOADJUVANT CHEMORADIATION IN ME- 

DIASTINAL LYMPH NODE METASTASES AS DETECTED BY F-18 FDG PET IN 

PATIENTS WITH NSCLC 

V. Prasad (Germany), M. Schmuecking, R. P. Baum, C. P. Schneider, N. Presselt, J. 

Leonhardi, K. Hoeffken, K. M. Mueller, T. Wendt, R. Bonnet 

PET SCAN GUIDED INTERSTITIAL BRACHYTHERAPY IN CERVICAL CANCER 

PATIENTS WITH CLINICALLY SUSPECTED RESIDUAL DISEASE 

D. N. Sharma (India), G. K. Rath, S. Kumar, R. Kumar, P. K. Julka, P. Jagadesan, V. 

Subramani 

RADIONUCLIDE EVALUATION OF RESPONSE TO NEOADJUVANT 

CHEMOTHERAPY IN BREAST CANCER PATIENTS 

O. Solodyannikova (Ukraine) 

RESPONSE EVALUATION FOLLOWING CHEMORADIATION WITH NELFI- 

NAVIR IN PANCREATIC CARCINOMA – IS FDG-PET CT RELIABLE? 

M. Scott-Brown (United Kingdom), A. Cavallaro, T. Brunner 

STUDY OF THE FOLLOW UP OF SUV AND VOLUME MEASUREMENT OF 

18FDG-PET POSITIVE TISSUES DURING RADIOTHERAPY 

K. Doyeux, A. Bak, A. Edet-Sanson, B. Dubray, S. Hapdey, D. Gensanne, P. Vera, 

VERA, 

I. Gardin (France) 

STAGING AND PREDICTION 

Abstract 

Nb. 

78 

79 

18F-FDG PET SUVMAX CORRELATES WITH HISTOLOGIC RESPONSE AF- 

TER RADIATION THERAPY FOR CERVICAL CANCER. 

J. Leseur (France), A. Devillers, D. Williaume, E. Le Prisé, C. Fougerou, R. de Crevoisier, 

E. Garin 

ARE TIMING OF CHEMORADIATION AND EARLY THERAPY RESPONSE AS 

DETECTED BY F-18 FDG PET PROGNOSTIC FACTORS OF A MULTIMODAL- 

ITY TREATMENT APPROACH FOR NSCLC STAGE III? 

R. P. Baum (Germany), M. Schmuecking, C. P. Schneider, V. Prasad, N. Presselt, J. 

Leonhardi, K. Hoeffken, K. M. Mueller, T. Wendt, R. Bonnet 


Abstract 

Nb. 

80 

81 

82 

83 

F-18 FLUORODEOXYGLUCOSE UPTAKE IN PRIMARY CERVICAL CANCER 

AND REGIONAL LYMPH NODES PREDICTS PROGNOSIS AFTER RADIATION 

THERAPY 

W. Sun (USA), S. Bhatia, M. Zimmerman, G. Jacobson 

MICROVASCULAR LEAKAGE AND CONTRAST ENHANCEMENT ARE PROG- 

NOSTIC FACTORS IN UNFAVORABLE LOW-GRADE GLIOMAS 

F. Dhermain (France), D. Ducreux 

POSITRON EMISSION TOMOGRAPHY (PET) METABOLIC ACTIVITY ASSOCI- 

ATED WITH INCREASED RISK OF DEATH IN SUPRAGLOTTIC CARCINOMA 

PATIENTS TREATED WITH CONCURRENT CHEMORADIATION. 

W. Skinner (USA), M. Chamarthy, D. Milstein, M. Haigentz, B. Schiff, R. Smith, S. 

Kalnicki, M. Garg 

STAGE IIIB OR IV NSCLC LUNG CANCER ON CT, WHAT IS THE POINT OF 

F-18 FDG PET/CT? 

J. Birchall (United Kingdom), M. Kumar, G. McCulloch 

TARGET SELECTION AND DELINEATION 

Abstract 

Nb. 

84 

85 

86 

87 

18F-FDG-PET-CT AUTOMATIC TUMOR CONTOURING FOR HEAD AND NECK 

CANCER RADIOTHERAPY: SIGNAL TO BACKGROUND RATIO METHOD 

L. A. Perez Romasanta (Spain), J. Velasco-Jimenez, M. Bellón-Guardia, E. Lozano, M. 

Sanz Martin, F. E. Mendicote Leon, A. Soriano-Castrejón 

4D PET/CT VALUTATION ON INTEGRATION AND IMPACT IN RADIATION 

THERAPY PLANNING OF LUNG TUMOR 

N. D’Abbiero, M. Paiusco (Italy), A. Versari, F. Fioroni, M. Iori, C. Iotti 

ADVANTAGES OF FIXED AND ADAPTIVE 18FDG PET/CT BASED BTV DELIN- 

EATION IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK : EF- 

FECT ON DOSE ESCALATED IMRT. 

M. I. Saunders (United Kingdom), R. Moule, I. Kyani, J. Dickson, C. Lemon, K. Goodchild 

BIOLOGICAL GROSS TUMOUR VOLUME (GTVB) IN HEAD AND NECK CAN- 

CER (HNC): COMPARISON OF AUTOMATED SEGMENTATION TOOLS. 

M. Lei (United Kingdom), J. Crawshaw, R. Jena, J. Scuffham, D. Rickard, S. Reise, M. 

Hatt, J. Hall, J. Sellinger, T. Jordan, S. Whitaker, N. Kirkby, D. Visvikis, A. Nisbet, M. T. 

Guerrero Urbano 


POSTERS

POSTERS 

Abstract 

Nb. 

88 

89 

90 

91 

92 

93 

94 

95 

96 

CHARACTERIZATION OF A TRIDIMENSIONAL THRESHOLD SEGMENTATION 

FOR PET TARGET VOLUME DELINEATION 

M. Loi (Italy), S. Piras, G. Fara, G. Meleddu, C. Meleddu 

DISCORDANCE OF TUMOR BOOST VOLUMES DEFINED USING DIFFERENT 

FUNCTIONAL MRI TECHNIQUES IN THE PROSTATE 

S. Riches (United Kingdom), S. Morgan, M. Partridge, G. Payne, D. P. Dearnaley, N. 

deSouza 

FOUR-DIMENSIONAL (4D) PET-CT IMAGING IN BASAL LUNG CANCER: DI- 

AGNOSTIC TECHNIQUE OR RADIOTHERAPEUTIC AID? 

G. Testanera (Italy), G. Carmela, M. Merra, S. Leonardi, M. Scorsetti, A. Chiti 

INVESTIGATING THE IMPACT OF THE HIGHLY VARIABLE LYMPHATIC 

DRAINAGE PATTERN IN PROSTATE CANCER PATIENTS 

L. Van den Bergh (Belgium), C. Deroose, S. Joniau, T. Budiharto, F. Mottaghy, E. Lerut, 

R. Oyen, F. Ameye, K. Bogaerts, H. Van Poppel, K. Haustermans 

MAGNETIC RESONANCE SPECTROSCOPY OF PROSTATE CANCER FOR RA- 

DIOTHERAPY TREATMENT PLANNING 

A. Coniglio (Italy), C. Guidi, R. Capparella, A. Santarelli, G. Freixas Vilches, S. La Civita, 

L. Begnozzi, A. Petrone, G. Mazzarella, L. Marmiroli 

MET-PET IN THE DELINEATION OF RESIDUAL GLIOBLASTOMA AFTER SUR- 

GICAL RESECTION 

R. Ciervide (Spain) 

OPTIMIZATION OF IMAGE RECONSTRUCTION PARAMETERS FOR FDG-PET- 

BASED TUMOUR DELINEATION 

M. Brambilla (Italy), R. Matheoud, P. Della Monica, G. Loi, L. Vigna, E. Inglese, M. 

Krengli 

PET PARTIAL VOLUME EFFECT INFLUENCE IN MANUAL TARGET VOLUMES 

DELINEATION IN EXTERNAL RADIOTHERAPY 

J. Santos (Portugal), A. Dias, R. Martins, F. Carrasco, J. Lencart, O. Sousa, M. Borges, 

C. Torres, A. Bastos 

PET/CT LESION DELINEATION FOR RTP USING A NOVEL VOLUME AND 

CONTRAST ADJUSTED THRESHOLD (VCAT) METHOD 

M. Aly (United Kingdom), P. Julyan, C. Rowbottom, B. Yap, M. Harris, D. Hastings 


Abstract 

Nb. 

97 

98 

99 

100 

101 

102 

103 

PET/CT WITH F18-FET AND F18-FDG FOR TARGET VOLUME DELINEATION 

IN STEREOTACTIC RADIOTHERAPY OF MALIGNANT CRANIAL BASE TU- 

MOURS 

D. D.Fahdt (Germany), M. Plotkin 

REIRRADIATION OF TUMOR RECURRENCE WITH 18FDG-PET GUIDANCE: 

EARLY OBSERVATION OF TOMOTHERAPY SERIES 

N. D’Abbiero (Italy), R. Dafne, P. Tamara, A. Muraglia, G. Maria, C. Iotti 

ROBUSTNESS AND REPRODUCIBILITY OF PET FUNCTIONAL VOLUMES AU- 

TOMATED DELINEATION: COMPARISON OF VARIOUS APPROACHES 

M. Hatt (France), C. Cheze Le Rest, O. Pradier, D. Visvikis 

TARGET VOLUME FOR PREOPERATIVE RADIOTHERAPY OF RECTAL CAN- 

CER: INFLUENCE OF PET/CT ON OBSERVERS VARIABILITY 

M. Krengli (Italy), B. Cannillo, L. Turri, E. Inglese, M. Brambilla 

TECHNIQUES TO DELINEATE HYPOXIC BTV USING 64CU-ATSM IN SQUA- 

MOUS CELL CARCINOMA OF THE HEAD AND NECK 

R. Moule (United Kingdom), I. Kyani, R. Paul, J. Dickson, M. O’Doherty, M. I. Saunders 

THE OPTIMAL WINDOW SETTING OF PET CO-REGISTERED WITH CT AND 

MRI IN TARGET LOCALIZATION FOR NASOPHARYNGEAL CARCINOMA 

V. Lee (Hong Kong (SAR) China), D. L. W. Kwong, P. L. Khong, D. Chua, S. Ng, K. W. 

Wong, K. S. Chan, T. W. Leung, G. Au 

USE OF FDG-4D-PET-CT FOR THE DELINEATION OF RADIOTHERAPY TAR- 

GET VOLUMES IN MALIGNANT LUNG LESIONS 

S. Kuechler, V. Duncker, F. Momm, E. Schubert, M. Hentschel, N. Hodapp, A. L. Grosu, 

W. Weber, U. Nestle (Germany), M. Mix 

TUMOUR CHARACTERISATION BY MOLECULAR IMAGING 

Abstract 

Nb. 

104 

105 

A BIOPHYSICAL TRANSPORT MODEL FOR PREDICTING TARGETED 

MACROMOLECULE TRANSPORT IN SOLID TUMORS 

S. Stapleton (Canada), M. Dunne, N. Chaudary, C. Allen, D. Jaffray 

CAPTOPRIL AND S-NITROSOCAPTOPRIL AS POTENT RADIOSENSITIZERS: 

COMPARATIVE STUDY AND UNDERLYING MECHANISMS. 

B. Jordan (Belgium), J. Peeterbroeck, O. Karroum, C. Diepart, J. Magat, V. Grégoire, B. 

Gallez 


POSTERS

POSTERS 

Abstract 

Nb. 

106 

107 

108 

109 

CHARACTERIZATION OF FLT-PET RESPONSE TO HIGH- AND LOW-DOSE 

RADIATION OF A LUNG CANCER XENOGRAFT IN MICE 

H. Keller (Canada), D. Vines, M. Lakshman, M. Dunne, P. Lindsay, D. Green, R. Clarkson, 

R. Bristow 

DIFFERENT METHODS OF QUANTITATIVE ANALYSIS FOR PATIENT- 

SPECIFIC DOSIMETRY: PLANAR VERSUS 90Y AND 111IN 3D IMAGING 

E. Grassi (Italy), F. Fioroni, A. Versari, D. Salvo, M. Iori 

EARLY THERAPY CHANGES IN VASCULAR PERMEABILITY PREDICT LONG 

TERM OUTCOME IN HEAD AND NECK CANCER 

D. Brizel (USA), D. Yoo, M. Carroll, J. MacFall, D. Barboriak, G. Broadwater, O. Craciunescu 

EFFECT OF SHORT AND LONG TERMED HYPOXIA ON THE UPTAKE OF 

[18F]EF5 AND [18F]FDG 

J. Sinkkonen (Finland), A. Silvoniemi, F. Sarita, N. Savisto, O. Solin, R. Grenman, P. 

Jaakkola, H. Minn, T. Grönroos 

110 HYPOXIA PET IMAGING: STATIC VERSUS DYNAMIC SCANS 

M. Busk (Denmark), M. R. Horsman, S. Jakobsen, K. V. Hansen, J. Bussink, A. Van Der 

Kogel, J. Overgaard 

111 

112 

113 

114 

115 

MR CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT AFTER AR- 

SENIC TRIOXIDE TREATMENT 

C. Diepart (Belgium), O. Karroum, J. Magat, B. Jordan, B. Gallez 

NON INVASIVE IMAGING OF CETUXIMAB-ZIRCONIUM-89 UPTAKE WITH PET 

SCANS: A PHASE I TRIAL 

J. Van Loon (Netherlands), H. Aerts, D. De Ruysscher, M. Öllers, A. M. Dingemans, M. 

Hochstenbag, G. Van Dongen, P. Lambin 

NON INVASIVE MAPPING OF SPONTANEOUS FLUCTUATIONS OF TUMOR 

OXYGENATION USING 19F-MRI 

J. Magat (Belgium), B. Jordan, B. Gallez 

OPTIMIZED PRODUCTION OF F-LABELED TRACERS ON NEW FULLY AUTO- 

MATED SYNTHESIS PLATFORM 

C. Sauvage (Belgium) 

PROGNOSTIC VALUE OF PRE-RADIOTHERAPY FDG-PET IN ADVANCED 

HODGKIN’ S DISEASE TREATED BY BEACOPP CHEMOTHERAPY REGIMEN 

S. Chiesa (Italy), M. C. De Santis, L. Teofili, S. Manfrida, B. Vannata, V. Frascino, A. 

Fiorentino, L. Calcagni, S. Hohaus, M. Balducci 


Abstract 

Nb. 

116 

117 

118 

QUANTITATIVE IN VIVO DCE MRI OF PROSTATE CANCER XENOGRAFTS: AS- 

SESSMENT OF ADT AND RT EFFICACY 

K. Røe (Norway), T. Seierstad, A. Kristian, G. M. Mælandsmo, A. Van Der Kogel, A. H. 

Ree, D. R. Olsen 

SIMAXSUV, A NEWLY SUGGESTED FDG-PET PARAMETER AS A PROGNOS- 

TIC PREDICTOR IN DIFFUSE LARGE B-CELL LYMPHOMA NEW CASES. 

A. Abd El-Ghany (Egypt), W. W. Lee 

VISUAL AND QUANTITATIVE EVALUATION OF FDG METABOLISM DURING 

CYTOTOXIC TREATMENT IN TWO PROSPECTIVE CLINICAL TRIALS WITH 

CORRELATION TO TUMOUR CONTROL 

E. Brun (Sweden), M. Bjurberg, E. Kjellen 


POSTERS

author’S index

author’s Index 

Index 

Abd El-Ghany A., 117 

Abedinpour P., 65 

Abolmaali N., 36 

Abramyuk A., 36 

Adebahr S., 43 

Aebersold D. M., 51, 67 

Aerts H., 112 

Agarwal J. P., 68 

Albarghach N., 53 

Alber M., 9, 26 

Allen A., 39 

Allen C., 64, 104 

Alongi F., 33 

Aly M., 96 

Ameye F., 91 

Anand A., 45 

Appold S., 36 

Aristophanous M., 29 

Arnold A., 51 

Au G., 102 

Badulescu A., 37 

Badulescu F., 37 

Bailey D., 46 

Bak A., 77 

Baldetorp B., 65 

Baldock C., 46 

Balducci M., 115 

Ball D., 41 

Balogh J., 70 

Barboriak D., 108 

Barisonzi R., 47 

Bastos A., 95 

Batatia H., 57 

Baum R. P., 73, 79 

Baumann M., 18, 36 

Bayouth J., 49 

27 

Bazalova M., 72 

Begnozzi L., 92 

Belderbos J., 28 

Bellón-Guardia M., 84 

Berardi G., 33 

Berbeco R., 29 

Bergmann R., 18 

Bernhardt P., 62 

Berry I., 61 

Beuthien-Baumann B., 8, 18 

Bhatia S., 80 

Birchall J., 83 

Bjurberg M., 65, 118 

Blumstein C., 67 

Blumstein N., 51, 54, 67 

Boellaard R., 6 

Boelling T., 24 

Boerman O., 10, 35 

Bogaerts K., 91 

Bohn P., 44 

Boltze C., 54 

Bonnet R., 73, 79 

Borasi G., 63 

Borges M., 95 

Borgström P., 65 

Boutry S., 71 

Bouzin C., 71 

Brainovich V., 56 

Brambilla M., 94, 100 

Brenner W., 21 

Brillouet S., 57 

Bristow R., 106 

Brizel D., 108 

Broadwater G., 108 

Brun E., 65, 118 

Brunner T., 76 

Brüchner K., 18 


AUThOR’S INDEx

AUThOR’S INDEx 

Bucher S., 43 

Budiharto T., 91 

Buether F., 24 

Bujko K., 23 

Busk M., 110 

Bussink J., 10, 35, 110 

Calabrese L., 59 

Calcagni L., 115 

Caldwell C., 70 

Callahan J., 41 

Campbell S., 70 

Candreia C., 51 

Cannillo B., 100 

Capparella R., 92 

Carmela G., 90 

Carrasco F., 95 

Carroll M., 108 

Caselles O., 57 

Catalaa I., 61 

Cavallaro A., 76 

Celsis P., 61 

Chamarthy M., 82 

Chan K. S., 102 

Chaudary N., 104 

Chen A., 29 

Chen E., 30 

Cheze Le Rest C., 53, 99 

Chiacchiararelli L., 56 

Chiesa S., 115 

Chiti A., 42, 47, 90 

Chua D., 102 

Cicone F., 56 

Ciervide R., 93 

Clarkson R., 106 

Comans E., 15, 16 

Comtat C., 60 

Coniglio A., 92 

Cormack R., 40 

Courbon F., 57 

Cozzarini C., 33 

Craciunescu O., 108 

Crawshaw J., 87 

Crisan A. E., 37 

D’Abbiero N., 85, 98 

D’Amico A., 40 

D’Arienzo M., 56 

D.Fahdt D., 97 

DaCosta R., 30 


Dafne R., 98 

Damen E., 28 

Davidson J., 70 

Davidson T., 39 

Dawood M., 24 

de Bree R., 15, 16 

de Crevoisier R., 78 

De Ruysscher D., 25, 28, 112 

De Santis M. C., 115 

Dearnaley D. P., 89 

Decristoforo C., 2 

Della Monica P., 94 

Deroose C., 34, 91 

deSouza N., 89 

Devillers A., 78 

Dewhirst M., 12 

Dhermain F., 81 

Di Muzio N., 33 

Dias A., 95 

Dickson J., 86, 101 

Diepart C., 105, 111 

Dierickx L., 57 

Dinescu S., 37 

Dingemans A. M., 112 

Dinshaw K., 68 

Doyeux K., 77 

Dubois L., 11, 66 

Dubray B., 44, 77 

Ducreux D., 81 

Duncker V., 103 

Dunne M., 104, 106 

Dziuk M., 23 

Eble M., 27 

Edet-Sanson A., 44, 77 

Enepekides D., 70 

Ernst I., 24 

Evans P., 52 

Everitt S., 41 

Fahdt D., 21 

Fara G., 88 

Feron O., 12, 71 

Finsterbusch F., 54 

Fiorentino A., 115 

Fioroni F., 63, 85, 107 

Flatmark K., 69 

Folkvord S., 69 

Fougerou C., 78 

Franceries X., 61 

AUTHOR INDEX 

AUTHOR INDEX 

Frascino V., 115 

Freixas Vilches G., 92 

Galassi R., 17 

Gallez B., 71, 105, 111, 113 

Gallina A., 63 

Gardin I., 44, 77 

Garg M., 82 

Garin E., 78 

Gebhard S., 67 

Gensanne D., 77 

Gerundini P., 59 

Geworski L., 21 

Geyer H., 54 

Ghosh-Laskar S., 68 

Giaccia A., 72 

Gianolli L., 33 

Gizewska A., 23 

Gjertsson P., 62 

Goel V., 45 

Golding R., 15 

Goodchild K., 86 

Graf R., 21 

Grassi E., 107 

Graves E., 72 

Green D., 106 

Greinke R., 18 

Grenman R., 109 

Grigsby P., 22 

Gross B., 49 

Grosu A. L., 43, 103 

Grégoire V., 71, 105 

Grönroos T., 109 

Guerrero Urbano M. T., 87 

Guidi C., 92 

Gupta K., 45 

Gupta T., 68 

Haigentz M., 82 

Hall J., 87 

Halldin C., 5 

Hansen K. V., 110 

Hany T. F., 13 

Hapdey S., 44, 77 

Harada H., 48 

Harris M., 96 

Hastings D., 96 

Hatt M., 53, 87, 99 

Haustermans K., 31, 34, 91 

Henriksson O., 62 

Hentschel M., 43, 103 

Hessel F., 18 

Hicks R., 41 

Higgins K., 70 

Hill R., 30 

Himmelman J., 62 

Hiraoka M., 48 

Hochstenbag M., 112 

Hodapp N., 103 

Hoeben B., 10 

Hoeffken K., 73, 79 

Hoekstra O., 15, 16 

Hoffmann A., 35 

Hohaus S., 115 

Holy R., 27 

Horsman M. R., 110 

Hultborn R., 62 

Högberg J., 62 

Inglese E., 94, 100 

Iori M., 63, 85, 107 

Iotti C., 85, 98 

Itasaka S., 48 

Jaakkola P., 109 

Jacobson G., 49, 80 

Jaffray D., 30, 64, 104 

Jagadesan P., 74 

Jain S., 68 

Jakobsen S., 110 

Janssen M., 11 

Jena R., 87 

Joniau S., 91 

Jordan B., 71, 105, 111, 113 

Jordan T., 87 

Julka P. K., 74 

Julyan P., 96 

Kaanders J., 9, 10, 35 

Kalnicki S., 82 

Karroum O., 105, 111 

Keller H., 106 

Ken S., 61 

Kepka L., 23 

Kesner A., 58 

Khong P. L., 102 

Killoran J., 29 

Kim Y., 55 

Kirkby N., 87 

Kjellen E., 65, 118 


AUThOR’S INDEx


Klotz J., 27 

Kolb H., 11, 66 

Kolodziejczyk M., 23 

Kotzerke J., 36 

Krause T., 51 

Kraxner P., 24 

Krengli M., 94, 100 

Kristian A., 116 

Krohn T., 27 

Kron T., 41 

Kuechler S., 103 

Kuik D. J., 15, 16 

Kumar M., 83 

Kumar R., 74 

Kumar S., 74 

Kurzeder C., 67 

Kusano M., 70 

Kwong D. L. W., 102 

Kyani I., 86, 101 

La Civita S., 92 

Lakeman A., 28 

Lakshman M., 106 

Lambertini R., 59 

Lambin P., 11, 66, 112 

Lambrecht M., 34 

Landoni C., 33 

Laprie A., 61 

Lartizien C., 60 

Lattuada P., 42, 47 

Laurent S., 71 

Laverman P., 10 

Le Maitre A., 53 

Le Prisé E., 78 

Lee V., 102 

Lee W. W., 117 

Leemans C. R., 15, 16 

Lei M., 87 

Lemon C., 86 

Lencart J., 95 

Leo R., 59 

Leonardi L., 47 

Leonardi S., 90 

Leonhardi J., 73, 79 

Lerut E., 91 

Leseur J., 78 

Leung M., 30 

Leung T. W., 102 

Lieuwes N., 11, 66 

Lindsay P., 30, 106 

Lio F., 17 


Loi G., 94 

Loi M., 88 

Longari V., 59 

Lotterie J. A., 61 

Lozano E., 84 

Lubrano V., 61 

Mac Manus M., 41 

MacFall J., 108 

MacKenzie R. G., 70 

Magat J., 71, 105, 111, 113 

Mahieu I., 71 

Makrigiorgos M., 40 

Malik J., 49 

Malinen E., 50 

Manca E., 33 

Manfrida S., 115 

Maria G., 98 

Marmiroli L., 92 

Marotta G., 59 

Maroy R., 60 

Martins R., 95 

Marx C., 54 

Marzullo A., 17 

Matheoud R., 94 

Matteucci F., 17 

Mazzarella G., 92 

McCulloch G., 83 

McGuire S., 49 

Meleddu C., 88 

Meleddu G., 88 

Menard J., 44 

Menda Y., 49 

Mendicote Leon F. E., 84 

Merlet P., 60 

Merra M., 90 

Messa C., 33 

Metwaly H., 61 

Michel R., 21 

Milstein D., 82 

Minn H., 14, 109 

MIshra A., 45 

Mix M., 43, 103 

Modugno A., 47 

Momm F., 103 

Moretti A., 17 

Morgagni P., 17 

Morgan S., 89 

Moro A., 17 

Mortelmans L., 34 

Mosch B., 18 

AUTHOR INDEX 

AUTHOR INDEX 

Mottaghy F., 27, 91 

Moule R., 86, 101 

Moustakis C., 24 

Moyal-Cohen-Jonathan E., 61 

Mueller K. M., 73, 79 

Muller R., 71 

Muraglia A., 98 

Mäding P., 18 

Mælandsmo G. M., 116 

Mönnich D., 9 

Nalis J., 57 

Navarria P., 42 

Nelson G., 72 

Nestle U., 20, 43, 103 

Ng S., 102 

Nguyen P., 40 

Nisbet A., 87 

Nitrosi A., 63 

Nussen S., 27 

Nuyts J., 19 

Nyuyki F., 21 

O’Doherty M., 101 

Offermann C., 43 

Olsen D. R., 50, 69, 116 

Oosterwijk E., 10 

Ouskili Z., 57 

Overgaard J., 110 

Oyen R., 91 

Oyen W., 9, 10, 35 

Paiusco M., 85 

Park S. J., 29 

Partridge M., 38, 52, 89 

Paul R., 101 

Payne G., 89 

Peeterbroeck J., 105 

Penninckx F., 34 

Perez Romasanta L. A., 84 

Perner S., 54, 67 

Perrin R., 38 

Petit S., 28 

Petrone A., 92 

Picchio M., 33 

Pinkawa M., 27 

Piras S., 88 

Piroth M., 27 

Plotkin M., 21, 97 

Ponto L., 49 

Poon I., 70 

Popescu C., 37 

Pradier O., 53, 99 

Prasad V., 73, 79 

Presselt N., 73, 79 

Purandare N., 68 

Pérez J., 72 

Radermacher K., 71 

Rangarajan V., 68 

Rath G. K., 74 

Ree A. H., 116 

Reiffenstuhl C., 36 

Reise S., 87 

Reshef A., 39 

Reske S., 54, 67 

Riches S., 89 

Rickard D., 87 

Rizell M., 62 

Rodari M., 42 

Roels S., 34 

Rognoni M., 59 

Rowbottom C., 96 

Røe K., 69, 116 

Saini G., 45 

Saint Christophe L., 60 

Salles A., 44 

Salvo D., 63, 107 

Salz H., 54 

Santarelli A., 92 

Santos J., 95 

Sanz Martin M., 84 

Sarita F., 109 

Saunders M. I., 86, 101 

Sauvage C., 114 

Savisto N., 109 

Schenker M., 37 

Schiff B., 82 

Schmuecking M., 51, 54, 67, 73, 79 

Schneider C. P., 73, 79 

Schneider-Kolsky M., 41 

Schober O., 24 

Schubert E., 103 

Schwaiger M., 1 

Schäfers K., 24 

Schütze C., 18 

Scopinaro F., 56 

Scorsetti M., 42, 47, 90 

Scott-Brown M., 76 


AUThOR’S INDEx


Scuffham J., 87 

Secrest J., 11, 66 

Seierstad T., 69, 116 

Sellinger J., 87 

Senft A., 15 

Sghedoni R., 63 

Sharma D. N., 74 

Shirvan A., 39 

Silvoniemi A., 109 

Singh S., 70 

Sinkkonen J., 109 

Skinner W., 82 

Skretting A., 69 

Smith B., 70 

Smith R., 82 

Soevik A., 50 

Solin O., 109 

Solodyannikova O., 75 

Sonke J. J., 28 

Sonveaux P., 12 

Soriano-Castrejón A., 84 

Sousa O., 95 

South C., 52 

Sridhar S., 40 

Stapleton S., 104 

Steinbach J., 36 

Steinmetz A., 39 

Stroobants S., 3 

Subramani V., 74 

Sun W., 80 

Supuran C., 66 

Szalus N., 23 

Tamara P., 98 

Teofili L., 115 

Testanera G., 47, 90 

Thames H., 18 

Thiberville L., 44 

Thorwarth D., 9 

Tomé W., 55 

Torres C., 95 

Trebossen R., 60 

Troost E., 9, 35 

Turri L., 100 

Van Cutsem E., 34 

Van den Bergh L., 91 

Van Der Kogel A., 110, 116 

Van der Putten L., 16 

van der Salm A., 28 


van der Stoep J., 28 

Van Dongen G., 7, 11, 112 

van Elmpt W., 28 

Van Loon J., 112 

Van Poppel H., 91 

Vander Elst L., 71 

Vannata B., 115 

Velasco-Jimenez J., 84 

Vena D., 70 

Vera VERA P., 44, 77 

Verdecchia 

verdecchia G. M., 17 

Versari A., 63, 85, 107 

Vieillevigne L., 61 

Vigna L., 94 

Vilalta M., 72 

Vines D., 106 

Visvikis D., 53, 87, 99 

Vitkin A., 30 

Végran F., 12 

Webb S., 38 

Weber W., 32, 43, 103 

Weckesser M., 24 

Wendt T., 54, 73, 79 

Wennerberg J., 65 

Whitaker S., 87 

Wiedenmann N., 43 

Williaume D., 78 

Willich N., 24 

Willowson K., 46 

Windhorst A., 11 

Wong K. W., 102 

Wouters B., 4, 66 

Yap B., 96 

Yap J., 29 

Yaromina A., 18 

Yoo D., 108 

Zawadzka A., 23 

Zbären P., 51 

Zerdoud S., 57 

Zhang J., 11 

Zheng J., 64 

Zimmerman M., 80 

Zips D., 18, 36 

Zito F., 59 

Ziv I., 39 

Zöphel K., 36 

Öllers M., 11, 28, 112 

AUTHOR INDEX 

Notes 

MIRO • Programme & exhibition guide Page 51

Notes 

Page 52 Programme & exhibition guide • MIRO

Molecular Imaging in Radiation Oncology - Estro-events.org

Create successful ePaper yourself

Delete template?

Save as template?